vTv Therapeutics Inc. (VTVT)
20.95
0.64 (3.15%)
At close: Apr 24, 2025, 10:35 AM
3.15% (1D)
| Bid | 18.5 |
| Market Cap | 54.73M |
| Revenue (ttm) | 1.02M |
| Net Income (ttm) | -18.46M |
| EPS (ttm) | -3.2 |
| PE Ratio (ttm) | -6.55 |
| Forward PE | -4.24 |
| Analyst | Buy |
| Ask | 22.49 |
| Volume | 1,355 |
| Avg. Volume (20D) | 22,854 |
| Open | 20.37 |
| Previous Close | 20.31 |
| Day's Range | 20.37 - 20.95 |
| 52-Week Range | 12.12 - 29.19 |
| Beta | 0.81 |
About VTVT
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is a...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2015
Employees 23
Stock Exchange NASDAQ
Ticker Symbol VTVT
Website https://www.vtvtherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is $35.5, which is an increase of 69.45% from the latest price.
Stock Forecasts1 month ago
+53.13%
vTv Therapeutics shares are trading higher after t...
Unlock content with
Pro Subscription
8 months ago
-24.53%
vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.
